BACKGROUND: Only a few studies have assessed cardiovascular risk factors (CRFs) in childhood cancer survivors. We determined the prevalence of CRFs in long-term survivors of acute lymphoblastic leukemia (ALL) and Wilms tumor. PROCEDURE: Adult survivors of ALL and Wilms tumor treated with radiotherapy and chemotherapy (RT + CT) or treated with chemotherapy alone (CT) were compared with sibling controls. CRFs (hypertension, diabetes mellitus, hypercholesterolemia, obesity, renal insufficiency) and hormonal deficiencies were assessed in each participant. Multivariate logistic regression analysis was used to evaluate the association between CRFs and treatment. RESULTS: Seventy-nine ALL, 62 Wilms tumor survivors, and 69 control subjects (mean ages 24.5, 25.9, and 26 years, respectively) were enrolled. Mean follow-up time since cancer treatment was 20.8 years. In the Wilms RT + CT group significantly more survivors had hypertension (21.6% vs. 1.4%, P < 0.001) and renal insufficiency (8.1% vs. 0%, P = 0.016) compared to controls. There were also more patients with multiple CRFs in the Wilms RT + CT group (16.2% vs. 2.9% in controls, P = 0.019). Almost 15% of ALL RT + CT survivors had growth hormone deficiency. Hypogonadism was seen in 18.9% of survivors in the Wilms RT + CT group. We observed no significant differences between CT-treated survivors of both malignancies and controls. The adjusted odds ratio for the occurrence of at least one CRF was 2.6 increased for survivors following abdominal radiotherapy. Treatment with CT alone was not associated with the occurrence of multiple CRFs. CONCLUSIONS: Long-term survivors of ALL and Wilms tumor have unfavorable CRFs due to previous RT not CT. Copyright 2010 Wiley-Liss, Inc.
BACKGROUND: Only a few studies have assessed cardiovascular risk factors (CRFs) in childhood cancer survivors. We determined the prevalence of CRFs in long-term survivors of acute lymphoblastic leukemia (ALL) and Wilms tumor. PROCEDURE: Adult survivors of ALL and Wilms tumor treated with radiotherapy and chemotherapy (RT + CT) or treated with chemotherapy alone (CT) were compared with sibling controls. CRFs (hypertension, diabetes mellitus, hypercholesterolemia, obesity, renal insufficiency) and hormonal deficiencies were assessed in each participant. Multivariate logistic regression analysis was used to evaluate the association between CRFs and treatment. RESULTS: Seventy-nine ALL, 62 Wilms tumor survivors, and 69 control subjects (mean ages 24.5, 25.9, and 26 years, respectively) were enrolled. Mean follow-up time since cancer treatment was 20.8 years. In the WilmsRT + CT group significantly more survivors had hypertension (21.6% vs. 1.4%, P < 0.001) and renal insufficiency (8.1% vs. 0%, P = 0.016) compared to controls. There were also more patients with multiple CRFs in the WilmsRT + CT group (16.2% vs. 2.9% in controls, P = 0.019). Almost 15% of ALL RT + CT survivors had growth hormone deficiency. Hypogonadism was seen in 18.9% of survivors in the WilmsRT + CT group. We observed no significant differences between CT-treated survivors of both malignancies and controls. The adjusted odds ratio for the occurrence of at least one CRF was 2.6 increased for survivors following abdominal radiotherapy. Treatment with CT alone was not associated with the occurrence of multiple CRFs. CONCLUSIONS: Long-term survivors of ALL and Wilms tumor have unfavorable CRFs due to previous RT not CT. Copyright 2010 Wiley-Liss, Inc.
Authors: Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544
Authors: Fang Fang Zhang; Michael J Kelly; Edward Saltzman; Aviva Must; Susan B Roberts; Susan K Parsons Journal: Pediatrics Date: 2014-02-17 Impact factor: 7.124
Authors: Matthew C Hocking; Lisa A Schwartz; Wendy L Hobbie; Branlyn Werba Derosa; Richard F Ittenbach; Jun J Mao; Jill P Ginsberg; Anne E Kazak Journal: Pediatr Blood Cancer Date: 2012-03-20 Impact factor: 3.167
Authors: Austin L Brown; Philip J Lupo; Heather E Danysh; Mehmet F Okcu; Michael E Scheurer; Kala Y Kamdar Journal: J Pediatr Hematol Oncol Date: 2016-08 Impact factor: 1.289
Authors: E Sieswerda; R L Mulder; I W E M van Dijk; E C van Dalen; S L Knijnenburg; H J H van der Pal; M S Mud; R C Heinen; H N Caron; L C M Kremer Journal: J Cancer Surviv Date: 2013-04-30 Impact factor: 4.442
Authors: Todd M Gibson; Zhenghong Li; Daniel M Green; Gregory T Armstrong; Daniel A Mulrooney; DeoKumar Srivastava; Nickhill Bhakta; Kirsten K Ness; Melissa M Hudson; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-22 Impact factor: 4.254
Authors: Anna Petryk; K Scott Baker; Brigitte Frohnert; Antoinette Moran; Lisa Chow; Alan R Sinaiko; Lyn M Steffen; Joanna L Perkins; Lei Zhang; James S Hodges; Julia Steinberger Journal: Pediatr Blood Cancer Date: 2012-09-21 Impact factor: 3.167